The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Clinical study on Huangqi Injection combined with methylprednisolone in treatment of multiple sclerosis
Author(s): 
Pages: 517-520
Year: Issue:  4
Journal: World Phytomedicines

Keyword:  Huangqi InjectionMethylprednisolone Sodium Succinate for injectionPrednisone Acetate Tabletsmultiple sclerosisSI of PBMC;
Abstract: Objective To investigate the clinical effect of Huangqi Injection combined with methylprednisolone in treatment of multiple sclerosis. Methods Patients(78 cases) with multiple sclerosis in Department of Neurology of the Third Hospital of Mianyang from June 2014 to August 2015 were randomly divided into control(n = 39) and treatment(n = 39) groups. The patients in the control group were iv administered with Methylprednisolone Sodium Succinate for injection, 1.0 g added into normal saline 500 m L, once daily. And they were po administered with Prednisone Acetate Tablets after 5 d, 60 mg/time, once daily. The dosage of Prednisone Acetate Tablets was gradually reduced after one week, minus 10 mg every five days until completely stopped. The patients in the treatment group were iv administered with Huangqi Injection on the basis of the control group, 30 m L added into 5% glucose solution 250 m L, once daily. The patients in two groups were treated for six weeks. After treatment, the efficacy was evaluated, and the changes of EDSS scores, SI of PBMC, IL-23, and IL-17 in two groups before and after treatment were compared. Results After treatment, the efficacies in the control and treatment groups were 74.36% and 92.31%, respectively, and there were differences between two groups(P < 0.05). After treatment, EDSS scores, SI, IL-23, and IL-17 in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Huangqi Injection combined with methylprednisolone has clinical curative effect in treatment of multiple sclerosis, and can decrease the serum level of IL-23, IL-17, also can inhibit the proliferation and activation of PBMC, which has a certain clinical application value.
Related Articles
No related articles found